Objective: To assess in vivo the expression of phosphodiesterase 4 (PDE4) and its relevance to cognitive symptoms in patients with Parkinson disease (PD) using [
rats and monkeys with working memory deficits, suggesting a key role of cAMP/PKA pathways in the modulation of executive dysfunction. 7 We investigated in vivo the expression of PDE4 and its relevance to cognitive deficits in patients with PD, using PET with [ 11 C] rolipram, which is a selective PDE4 radioligand for human use. 8 As age-related reduction in PDE4 expression in healthy individuals older than 55 years has not been investigated, we also explored the influence of age in our cohort of healthy controls.
Our findings suggest loss of PDE4 expression in striato-thalamo-cortical network in patients with PD, which is associated with working memory deficits.
METHODS Participants and clinical characteristics.
Twelve patients with a diagnosis of idiopathic PD according to the Queen Square Brain Bank criteria were recruited from specialist movement disorders clinics at the National Hospital of Neurology & Neurosurgery, Queen Square, London, UK (table 1) . None of these patients fulfilled the diagnostic criteria of PD mild cognitive impairment or PD dementia. 9, 10 Twelve healthy individuals with no history of neurologic or psychiatric disorders were recruited as control group. To assess the effect of age on PDE4 expression, we studied a younger (n 5 6; 5 male; mean age 6 SD 5 39.0 6 8.4; age range 5 26-52 years) and an older (n 5 6; 5 male; mean age 6 SD 5 66.3 6 3.6; age range 5 53-78 years) subgroup of healthy controls.
Participants had no history of other neurologic or psychiatric disorders, were not taking substances with known actions in PDEs (e.g., apremilast, cilomilast, luteolin, piclamilast, roflumilast, and ibudilast), and had no contraindications to undertake PET and MRI scanning according to scanning safety criteria (mrisafety.com; https://www.gov.uk/government/ publications/arsac-notes-for-guidance).
Patients with PD were all on levodopa treatment. Daily and lifetime dopaminergic medication dose was calculated with a formula based on the theoretical equivalence to levodopa. 11 Motor symptom severity was assessed with the Unified Parkinson's Disease Rating Scale part III and according to Hoehn & Yahr stage. Motor assessments were performed off medication after overnight withdrawal of the patient's dopaminergic medications. Neuropsychiatric symptoms were assessed with the Apathy Evaluation Scale, Beck Depression Inventory II (BDI-II), and the Hamilton Depression Rating Scale (HDRS). Nonmotor Symptoms Scale for PD was used to assess nonmotor symptoms. The Mini-Mental State Examination and Montreal Cognitive Assessment were used to assess general cognitive status. Further cognitive assessments were carried out using the Cambridge Neuropsychological Test Automated Battery (CANTAB) and included assessments related to psychomotor speed (Reaction Time), attention (Rapid Visual Information Processing), episodic memory (Paired Associate Learning and Delayed Match to Sample), working memory, and executive function (Spatial Working Memory; e-Methods at Neurology.org). CANTAB neuropsychological tests have been described in detail 12 and shown to be highly sensitive to deterioration in executive function in PD. 13 Quality of life was measured with the patient self-reported 39-item Parkinson's Disease Questionnaire.
Standard protocol approvals, registrations, and patient consents. The study was approved by the institutional review boards and the research ethics committee. Written informed consent was obtained from all study participants in accordance with the Declaration of Helsinki.
Imaging data analysis. MRI-based volumetric analysis. Since PDE4 is an intracellular enzyme, neuronal loss may affect PDE4 availability as measured with PET. We investigated volumetric changes in cortical and subcortical nuclei regions in our cohort of patients with PD compared to all healthy controls. FreeSurfer Table 1 Clinical Neuropsychiatric assessments showed significant differences between healthy controls and patients with PD (BDI-II: p , 0.05; HDRS: p , 0.05); however, the neuropsychiatric burden in our cohort of patients with PD was minimal and did not meet the cutoff score for depression.
Volumetric analysis. FreeSurfer analysis showed no volumetric differences in cortical and subcortical nuclei ROIs between the groups of patients with PD and all healthy controls (table e-2). Moreover, no significant associations were observed between cortical and subcortical volumes and [ Effect of age on PDE4 expression. We found no significant differences in cortical and subcortical nuclei ]rolipram PET molecular imaging in vivo, we report loss of PDE4 expression within the striato-thalamo-cortical brain circuitry of patients with PD, which is associated with spatial working memory deficits. Our findings demonstrate 16%-32% loss of PDE4 expression in the striatum, thalamus, hypothalamus, and frontal cortex of patients with PD who had episodic and working memory deficits, were on dopamine replacement therapy, but had no substantial brain atrophy in the ROIs examined.
PDE4 expression was decreased by 12%-32% within the thalamus, with most marked decreases observed in prefrontal and temporal lobe-projecting thalamic nuclei, whereas motor nuclei were less affected. Within the cortex, PDE4 expression in patients with PD was decreased by 11%-20%, with most marked decreases observed in the posterior dorsolateral frontal cortex, medial frontal cortex, and supplementary motor area, whereas the orbitofrontal cortex and frontal operculum were the least affected. We found lower PDE4 expression also in occipital regions, but this did not reach statistical significance, probably due to the high intersubject variability in [ 11 C]rolipram V T observed in these cortical regions. We found no differences in cortical and subcortical volumetric measures between patients with PD and healthy controls. It is possible that the group comparisons were insufficiently powered to detect significant differences in cortical and subcortical volumetric measures between the patients with PD and the healthy controls. Moreover, our group of patients with PD included early and advanced stages of the disease, with some patients with PD showing motor complications such as levodopa-induced dyskinesias (LIDs). Although cortical thinning has been associated with longer PD duration, 16 patients with PD with LIDs exhibited increased cortical thickness in the frontal cortex 17 and subcortical nuclei. 18 This could have also contributed to the lack of significant volumetric changes observed in our cohort of patients with PD. We also acknowledge as a limitation of this study that ROI [ 11 C]rolipram PET analysis was carried out using the anatomical CIC atlas, whereas cortical and subcortical volumetric changes were assessed with FreeSurfer, which could have contributed to some differences in terms of regions.
There are no previous clinical or preclinical studies investigating the expression of PDE4 in PD. Different lines of evidence in experimental animals confirm a clear role for PDE4 in modulating cognition, including working memory. PDE4 knockout mice show enhanced long-term depression and impaired long-term memory in a fear-conditioning paradigm, 19 and impaired spatial working memory. 20 In animal models of Huntington disease, decreased PDE4 protein levels and PKA hyperactivation in the hippocampus were associated with spatial memory deficits, suggesting that PDE4-dependent regulation of cAMP/PKA signaling cascade may be one molecular mechanism underlying cognitive decline. 21 In mice, intraperitoneal administration of the PDE4 inhibitor rolipram enhanced spatial working memory consolidation in the Morris water maze task. 22 In rodents, rolipram has been shown to improve working memory deficits caused by administration of scopolamine, a muscarinic receptor antagonist, 23 and MK-801, an NMDA antagonist. 24 Treatment with PDE4 inhibitors also ameliorated spatial working memory deficits in a transgenic mouse model of Alzheimer disease.
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PDE4 inhibitor-related increases in cAMP signals lead to memory enhancements, whereas increases in basal cAMP levels due to PDE4 loss lead to memory impairments. 26 This might explain why PDE4 inhibitors are beneficial in improving cognitive deficits in rodents.
In this study, we found significant associations between loss of PDE4 expression in the caudate, thalamic nuclei, and frontal cortices and spatial working memory deficits in patients with PD. The striatothalamo-cortical circuit has been closely linked to spatial working memory. The dorsolateral prefrontal cortex is part of the network mediating spatial working memory processes. 27 The medial frontal cortex plays an important role in performance monitoring on subsequent trials and in the implementation of associated adjustments in cognitive control. 28 Neuroimaging studies have shown a close interaction between the posterior medial frontal cortex and dorsolateral prefrontal cortex. 28 While the posterior medial frontal cortex controls for errors and sends the signal for adjustments, the dorsolateral prefrontal cortex in turn implements the necessary top-down control. 28 This functional interplay is also mediated by the supplementary motor area, which plays a role in spatial rehearsal, 29 and other subcortical structures such as the caudate and thalamic nuclei. Within the caudate, the precommissural dorsal caudate is the area of the striatum that receives the largest corticostriatal projections from the dorsolateral prefrontal cortex and is involved in spatial memory processes. 30 Output from the basal ganglia projects to the thalamus, which closes the circuit by projecting back to the dorsolateral frontal cortex. 31 Our findings show that, within the thalamus, loss of PDE4 expression only in the subregions connected to the prefrontal cortex is associated with spatial working memory deficits in patients with PD. Cognitive impairment is a very common feature of PD, affecting up to 57% of patients within the first 325 years after PD diagnosis, and adds substantially to patients' and carers' burden. 32 Spatial working memory is affected early in the course of the disease and may represent one of the premotor symptoms of PD. Recent evidence has shown that healthy people over age 50 who are at risk of developing PD (exhibiting hyposmia and dopamine transporter reduction) performed worse at cognitive tests assessing spatial working memory. 4 Previous functional MRI and H 2 15 O PET molecular imaging studies have shown that blood flow is reduced in the frontostriatal circuit while performing working memory tasks in patients with PD with and without cognitive impairment. 3, 33, 34 In agreement with these findings, we found significant correlations between worse performance in the spatial working memory tests and decreases in PDE4 expression in precentral gyrus, dorsolateral prefrontal cortex, medial frontal cortex, and precommissural dorsal caudate.
We have recently shown that another PDE, PDE10A, is decreased by 14%-28% in the striatum and pallidum of patients with moderate/advanced PD and loss of PDE10A expression is associated with the severity of motor symptoms and complications. 35 In comparison with PDE10A, which is mainly expressed in the basal ganglia, PDE4 is widely expressed in the cortex and subcortical regions intimately involved in cognitive processes. 5 Thus it is not surprising that we did not find significant decreases in PDE4 expression in subcortical nuclei specifically involved in the control of movement such as putamen and pallidum. Taking together our previous and recent findings, it is likely that while PDE10A plays a role in the control of movement, PDE4 is involved in the regulation of cognitive processes and both enzymes are decreased in patients with PD, leading to the manifestation of motor and cognitive symptoms.
We did not find correlations between PDE4 expression and disease duration. This may be explained by the wide cross-section in disease duration, ranging from 3 to 25 years of PD duration, and the small number of participants. Further longitudinal studies investigating PDE4 expression in a larger cohort of patients with PD spanning from the de novo to advanced stages are needed to elucidate the role of this enzyme in the course of the disease.
The PDE4 family comprises 4 isoforms: PDE4A, B, C, and D-which encode for distinct proteins. 8 Preclinical studies have shown that distinct subtypes of PDE4 isoforms differentially modulate synaptic activity and have distinct neurologic roles. 19, 20 PDE4B modulates long-term depression and loss of this isoform causes impaired spatial working memory, 20 whereas PDE4D regulates long-term potentiation and loss of this isoform leads to impaired fear conditioning in mice. 19 [
11 C]rolipram binds with high affinity to all 4 PDE4 isoforms, 8 thus it was not possible to investigate in humans the different role of PDE4 subtypes.
We also investigated the effect of age on PDE4 expression in a cohort of healthy controls. Preclinical studies have shown age-related reduction of PDE4 expression in the striatum and cortex of rodents and nonhuman primates. 36, 37 In the striatal and cortical brain tissue of aged rats (100 weeks old), [ 3 H]rolipram binding was decreased by 58%-69% compared to young rats (10 weeks old), 36 and [ 11 C]rolipram binding was decreased by 20%-25% in the striatum and frontal cortex of aged monkeys. 37 However, more recent work indicated that age does not affect [ 11 C] rolipram V T in cortical and subcortical regions of healthy controls and patients with major depressive disorder aged between 18 and 55 years. 38 Our findings are in agreement with the previous study in humans, and we report no age-related reduction in cortical and subcortical PDE4 expression in healthy controls spanning between 26 and 78 years of age. However, it is possible that the small number of healthy controls in each group studied could not reach statistical significance and the PDE4 agerelated changes observed in rodents might be explained by heterogeneity of PDE4 isoforms in different species. Further studies evaluating PD4 expression in a larger cohort of healthy controls spanning from 20 to 80 years of age are needed to clarify the effect of age on PDE4 expression.
Our findings show in vivo a neurochemical change in PD that is associated with working memory deficits. Novel PDE4 modulating drugs could potentially improve cognitive symptoms in PD.
AUTHOR CONTRIBUTIONS
M.P. conceived the study, conceptualized the experimental design, and acquired funding for the study. F.N., E.A.R., R.N.G., T.F., and M.A.M. gave input to experimental design. F.N. and G.P. performed the imaging and clinical assessments and acquired the data. F.N., G.P., E.A.R., and M.P. organized the study. F.N. and M.P. wrote the first draft and prepared the manuscript. F.N. and G.E.S. generated the figures. H.W., C.C., and G.E.S. analyzed the data. F.N., M.P., and T.F. interpreted the data. F.N., T.F., and G.P. recruited the participants. All authors revised and gave input to the manuscript.
